Stock Track | GENSCRIPT BIO Soars 5.45% Intraday on Sector Optimism and Strong Associate Performance

Stock Track
05/13

GENSCRIPT BIO's stock surged 5.45% during intraday trading on Wednesday, reflecting significant investor interest in the biotechnology company.

The price movement appears to be driven by multiple positive factors. Eli Lilly's recent $7 billion acquisition of biotech firm Kelonia continues to boost sentiment across the entire cell therapy sector. Additionally, GenScript's associate company Legend Biotech reported robust first-quarter sales of approximately $597 million for its core product CARVYKTI, representing a substantial 61.8% year-over-year increase.

Analyst sentiment remains positive, with Morgan Stanley maintaining an "Overweight" rating and a HK$16.5 target price, while CICC maintains an "Outperform" rating with a HK$17.90 target price, both significantly above the current trading level.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10